Kiniksa Pharmaceuticals International
Logotype for Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals International (KNSA) investor relations material

Kiniksa Pharmaceuticals International Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Kiniksa Pharmaceuticals International plc
Jefferies Global Healthcare Conference summary16 Nov, 2026

ARCALYST commercial performance

  • Growth is driven mainly by new patient enrollments; compliance, patient satisfaction and payer approval remain strong, with average treatment duration at ~3 years.

  • ~450 physicians prescribed ARCALYST for the first time in the latest quarter; ~30% of the prescribing pool have treated two or more patients, and just over 50% of quarterly enrollments come from repeat prescribers.

  • 5,450 physicians have prescribed ARCALYST since launch, versus an estimated 25,000–30,000 physicians seeing recurrent pericarditis patients annually; Q3 penetration was 23% of the 14,000 patients with two or more recurrences.

  • The estimated total eligible population is 40,000, including 26,000 patients at first recurrence; ~45% of patients who stop treatment later restart.

  • RESONANCE registry analyses found a 96%–98% lower recurrence risk with rilonacept versus transition to steroids in second-line use; first-recurrence patients showed similar risk reductions.

Pipeline and market opportunity

  • KPL-387 is in Phase III PASTORALE; Phase II results supported 300 mg SC every four weeks, with response in four days, CRP reduction or normalization in ~1 week, and inflammatory suppression across the monthly interval.

  • KPL-387 Phase III data are expected in H2 2027; the monthly liquid formulation may support an auto-injector, and management described it as wholly owned and outside the Regeneron profit split.

  • Market research found >75% of patients and >92% of healthcare professionals preferred KPL-387’s target profile for recurrent pericarditis treatment.

  • KPL-1161, a potentially quarterly IL-1α/β inhibitor, is expected to enter the clinic later in 2026.

  • Management emphasized dual IL-1α and IL-1β inhibition, citing their roles in local tissue response and downstream inflammatory amplification in recurrent pericarditis.

Financial outlook and capital allocation

  • FY2026 revenue guidance is $1.045 billion–$1.050 billion; management cited continued ARCALYST enrollment growth and market penetration as ongoing opportunities.

  • Higher manufacturing volumes and late-stage KPL-387 and KPL-1161 development were cited as contributors to increased SG&A; management described the business as profitable with a strong cash position.

  • Capital allocation will prioritize growth in the commercial and clinical pipeline, with a high bar for additional value-creating opportunities.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Kiniksa Pharmaceuticals International earnings date

Logotype for Kiniksa Pharmaceuticals International plc
Q4 202623 Feb, 2027
Kiniksa Pharmaceuticals International
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Kiniksa Pharmaceuticals International earnings date

Logotype for Kiniksa Pharmaceuticals International plc
Q4 202623 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines. The company's work targets debilitating diseases with significant unmet medical needs, particularly within cardiovascular and autoimmune disorders. Kiniksa's portfolio includes products and candidates based on strong biological rationale or validated mechanisms, offering potential differentiation in treatment approaches. The company is known for its flagship product, ARCALYST, which is used to treat certain inflammatory cardiovascular conditions. The company is headquarted in London, UK, and its shares are listed on the NASDAQ.